Major Program
Phase 0 I II Cancer Prevention Clinical Trials Program
Research Group
Breast and Gynecologic Cancer
Sponsor
National Cancer Institute (NCI)
Status
Active, not recruiting
NCT ID
NCT03036930
This phase II trial studies whether the nonavalent human papillomavirus vaccine given to adults prior to kidney transplantation can help the body build and maintain an effective immune response during the post-transplant period when they receive immunosuppressive drugs to prevent transplant rejection. This study will help inform our scientific understanding about vaccine-induced immune responses among immunosuppressed individuals.
Intervention
Biospecimen Collection, HPV Self-Collection, Questionnaire Administration, Recombinant Human Papillomavirus Nonavalent Vaccine
Condition
Human Papillomavirus Infection, Human Papillomavirus-Related Carcinoma
Investigators
Marc T Goodman